📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of otcs and supplements ii/2025 { "detected_language": "romanian", "translated_text": "lot-0005, title: oximed ® sau equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0015, title: betadine 30 ml®, iodine ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0048, title: bromhexine mcc 8 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0067, title: chlorhexidine digluconate, dermobacter maximum 125 ml® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0069, title: clotrimazole cream ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0075, title: fenistil gel ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0076, title: spaverin 40 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0077, title: no-spa 80 mg ®, spaverin 80 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0085, title: glycerin suppositories for adults or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0103, title: paduden rapid forte 400 mg ®, ibalgin forte ®, brufen 400mg, adagin forte 400mg or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0107, title: enterolactis plus or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0108, title: enterolactis drinkable or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0110, title: hepa-merz granules ® or equivalent, estimated value excluding vat: 3546184.20 ron.Centralized framework agreement for 24 months for the supply of otcs and supplements ii/2025